Juno Therapeutics (JUNO) is developing next-generation cancer therapies that use a patient's own immune system to find and destroy cancer cells.
Although the company doesn't have any drugs currently on the market, it hopes that a promising drug for adult lymphoblastic leukemia will succeed in mid stage studies and clear the way to an FDA filling in 2017.
Given high response rates to its most advanced drug and a timeline that could mean Juno Therapeutics begins generating sales within two years, investors boosted shares by 12.1% last month. In the following slideshow, I offer up additional insight into Juno Therapeutics intriguing approach and its timeline to commercialization.
The next billion-dollar iSecret
The world's biggest tech company forgot to show you something at its recent event, but a few Wall Street analysts and the Fool didn't miss a beat: There's a small company that's powering their brand-new gadgets and the coming revolution in technology. And we think its stock price has nearly unlimited room to run for early in-the-know investors! To be one of them, just click here.
Why Juno Therapeutics Jumped 12% in September from The Motley Fool
